Drugs / Alnuctamab
Alnuctamab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07219563 | Mar 2026 → Dec 2027 expected | systemic lupus erythematosus | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT06163898 | Feb 2024 → Jun 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT06121843 | Feb 2024 → Aug 2028 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 1 | NCT03486067 | Apr 2018 → Mar 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06232707 | May 2024 → Nov 2025 | plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alnuctamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06232707 ↗ |
| Known as | BMS-986349 | “This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate...” NCT07219563 ↗ |
| Known as | CC-93269 | “This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate...” NCT07219563 ↗ |
| Modality | Protein / enzyme biologic | “It is a special protein engineered in the laboratory, which is able to attach to T cells, a type of white blood cell that can kill other cells in the body.” NCT07219563 ↗ |
| Route | Intravenous | “CC-93269 administered intravenous (IV)” NCT03486067 ↗ |